MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "MAO-B inhibitors"

  • 2022 International Congress

    Central fatigue and glutamatergic overactivity in Parkinson’s disease: possible impact of safinamide

    C. Pauletti, N. Locuratolo, D. Mannarelli, A. Maffucci, A. Petritis, F. Fattapposta (Rome, Italy)

    Objective: The aim of the present study was to test the hypothesis that central fatigue in Parkinson’s disease (PD) could be related to high levels…
  • 2022 International Congress

    Improvement of movement disorder and neurodevelopment under selegiline in a CLTC deficient patient

    F. Nardecchia, L. Pannone, F. Manti, V. Muto, R. Bove, L. Pollini, M. Giannini, M. Tartaglia, S. Martinelli, V. Leuzzi (Rome, Italy)

    Objective: We report the significative improvement on both movement disorder and neurodevelopment in a 5-year-old CLTC deficient patient treated with selegiline. Background: In 2019 we described a 30-year-old woman…
  • 2022 International Congress

    SAFINAMIDE: REAL LIFE STUDY. EFFICACY IN SWITCH FROM RASAGILINA AND LOW-DOSE TREATMENT.

    MI. Morales-Casado, N. López-Ariztegui, DD. García-Meléndez, A. Diezma-Martín (Toledo, Spain)

    Objective: Evaluate the efficacy of safinamide in fluctuations in Parkinson's disease in real life. Analysis by subgroups: Switch rasagiline to safinamide and treatment with low…
  • 2022 International Congress

    Safinamide adherence: the experience of the movement disorder unit of Trieste.

    M. Catalan, M. Liccari, V. Tommasini, L. Antonutti, P. Manganotti (Trieste, Italy)

    Objective: Describe the clinical experience with Safinamide and assess the patients’ adherence to this treatment in the movement disorders centre of Trieste-Italy. Background: Safinamide (Xadago®)…
  • MDS Virtual Congress 2021

    Effects of safinamide adjunct therapy on non-motor symptoms in patients with Parkinson’s disease: a post-hoc analysis of the Japanese Phase 2/3 study

    N. Hattori, Y. Tsuboi, Y. Kogo, M. Koebisu, T. Ishida, I. Suzuki, M. Nomoto (Tokyo, Japan)

    Objective: To evaluate the efficacy of safinamide for mood and pain by a post-hoc analysis of the Japanese phase 2/3 double-blind study (JapicCTI-153056) in patients…
  • MDS Virtual Congress 2021

    Safinamide Improves Sleep and Daytime Sleepiness in Parkinson´s Disease. Results from the SAFINONMOTOR Study

    I. Cabo López, C. Labandeira Guerra, R. Yáñez Baña, MI. Cimas Hernando, JM. Paz González, MG. Alonso Losada, MJ. González Palmás, C. Martínez Miró, D. Santos García (Pontevedra, Spain)

    Objective: Our aim was to analyze the effectiveness of safinamide on sleep in Parkinson´s disease (PD) patients from the SAFINONMOTOR (an open-label study of the…
  • MDS Virtual Congress 2021

    Safinamide Improves Mood in Parkinson´s Disease. Results from the SAFINONMOTOR Study.

    C. Labandeira, MG. Alonso Losada, R. Yáñez Baña, I. Cimas Hernando, I. Cabo López, JM. Paz González, MJ. González Palmás, C. Martínez Miró, D. Santos García (Vigo, Spain)

    Objective: Our aim was to analyze the effectiveness of safinamide on mood in Parkinson´s disease (PD) patients from the SAFINONMOTOR (an open-label study of the…
  • MDS Virtual Congress 2021

    Improved Excessive Daytime Sleepiness with Selegiline in patients with Parkinson’s Disease: An Open Trial

    JR. Zhang, JP. Chen, J. Li, J. Li, CJ. Mao, CF. Liu (Suzhou, China)

    Objective: This study, an open-labeled trial, was aimed to assess the efficacy and safety of selegiline on the treatment of EDS in PD patients. Background: Excessive Daytime…
  • MDS Virtual Congress 2020

    Effects of Rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) Emotional Well-being Domain in Patients with Parkinson’s Disease (PD): A Post-Hoc Analysis of Clinical Trials in Japan

    N. Hattori, A. Takeda, Y. Hanya, T. Kitagawa, M. Arai, Y. Furusawa, H. Mochizuki, M. Nagai, R. Takahashi (Tokyo, Japan)

    Objective: To evaluate the direct and indirect effects of rasagiline on emotional well-being domain of the PDQ-39 in patients with PD by a post-hoc analysis…
  • MDS Virtual Congress 2020

    Impact of safinamide on non-motor and motor experiences of daily living: Primary results from the prospective, observational ProGo study

    S. Isaacson, T. Clinch, E. Farbman, R. Pahwa (Boca Raton, FL, USA)

    Objective: Evaluate the effect of safinamide treatment on non-motor and motor experiences of daily living as assessed using the MDS-UPDRS (Parts I nm-EDLand II m-EDL).…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 6
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • #23624 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Three cases of early tremor in the course of Guillain-Barré Syndrome
  • The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • The Role of MRI and DaTscan in Vascular Parkinsonism: A Case Report
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley